Achillion Appoints Brian Di Donato as Chief Financial Officer
February 11 2019 - 6:00AM
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage
biopharmaceutical company dedicated to transforming the lives of
patients and families affected by complement-mediated diseases,
today announced the appointment of Brian Di Donato to the position
of Senior Vice President and Chief Financial Officer, effective
immediately. Mr. Di Donato has over 20 years of financial and
leadership experience and will assume responsibility for finance,
accounting and treasury as well as continue to lead investor
relations.
“Brian joined the Achillion team in August 2018
and has already made significant contributions alongside the new
management team as we accelerate our clinical programs and prepare
for registrational trials,” commented Joseph Truitt, President and
Chief Executive Officer of Achillion. “His significant finance,
investing and leadership experience will greatly benefit Achillion
as we plan for late-stage development, commercialization and new
indications.”
Mr. Di Donato stated, “Achillion’s portfolio of
oral, small molecule complement inhibitors, is uniquely positioned
to potentially make a difference in the lives of patients with
complement-mediated diseases. I look forward to working closely
with our experienced leadership team to develop strategies
leveraging our strong cash position into near- and long-term
clinical and commercial opportunities to create value for patients
and Achillion shareholders.”
Mr. Di Donato is an experienced capital markets
banker, investor and fund manager, having previously held positions
as Managing Director and Co-Portfolio Manager at Sorin Capital
Management and President and Chief Investment Officer at Capmark
Investments. He previously worked in fixed-income capital markets
as an Executive Director at Morgan Stanley and Vice President at
UBS Securities. Mr. Di Donato holds a Master of Business
Administration from New York University’s Stern School of Business
as well as bachelors of science degrees in biology from Penn State
University and in mechanical engineering from Villanova University.
Prior to business school, he was an aerospace engineering officer
in the U.S. Navy.
About Achillion
PharmaceuticalsAchillion Pharmaceuticals, Inc.
(NASDAQ:ACHN) is a clinical-stage biopharmaceutical
company focused on advancing its oral, small molecule,
complement system inhibitors into late-stage development and
commercialization. Each of the drug candidates in the
Company’s portfolio was discovered in its laboratories and is
wholly owned. Achillion is initially focusing its drug
development activities on alternative pathway-mediated diseases
where there are no approved therapies or where existing therapies
are inadequate for patients. Initial indications being evaluated
for its compounds include paroxysmal nocturnal hemoglobinuria
(PNH), C3 glomerulopathy (C3G), and immune complex mediated
membranoproliferative glomerulonephritis (IC-MPGN). To advance its
investigational drugs into phase 3 and commercialization, the
Company plans to work closely with key stakeholders including
patients, payors, regulators and healthcare professionals.
More information is available at http://www.achillion.com.
InvestorsBrian Di DonatoSenior Vice President,
Chief Financial Officer Achillion Pharmaceuticals, Inc.Tel. (215)
709-3032bdidonato@achillion.com
Media:Jon PappasMedia RelationsW2O GroupTel.
(646) 847-0303jpappas@w2ogroup.com
Cautionary Note Regarding
Forward-Looking StatementsThis press release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 that are subject to risks,
uncertainties and other important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements. Achillion may use words such as
“expect,” “anticipate,” “project,” “target,” “intend,” “plan,”
“aim,” “believe,” “seek,” “estimate,” “can,” “could” “focus,”
“will,” “look forward,” “continue,” “goal,” “strategy,”
“objective,” “may,” “potential,” and similar expressions to
identify such forward-looking statements. These forward-looking
statements also include statements about: the potential benefits of
factor D inhibition as a treatment for complement-mediated
diseases; the potential benefits of, and indications for,
Achillion’s compounds that inhibit factor D, including ACH-4471,
ACH-5228 and ACH-5548; Achillion’s belief that its portfolio of
compounds could expand factor D portfolio opportunities, provide
strategic optionality or create significant value; Achillion’s
expectations regarding the advancement of, and timeline for
reporting results from, clinical trials of its product candidates
as well as its ability to advance additional compounds; and other
statements concerning Achillion’s strategic goals, efforts, plans,
and prospects. Among the important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements are risks relating to, among other
things, Achillion’s ability to: demonstrate in any current and
future clinical trials the requisite safety, efficacy and
combinability of its product candidates; advance the preclinical
and clinical development of its complement factor D inhibitors
under the timelines it projects in current and future preclinical
studies and clinical trials; enroll patients in its clinical trials
on its projected timelines; obtain and maintain patent protection
for its product candidates and the freedom to operate under third
party intellectual property; obtain and maintain necessary
regulatory approvals, and the granting of orphan designation does
not alter the standard regulatory requirements and process for
obtaining such approval; establish commercial manufacturing
arrangements; identify, enter into and maintain collaboration and
other commercial agreements with third-parties; compete
successfully in the markets in which it seeks to develop and
commercialize its product candidates and future products; manage
expenses; manage litigation; raise the substantial additional
capital needed to achieve its business objectives; and successfully
execute on its business strategies. These and other risks are
described in the reports filed by Achillion with the U.S.
Securities and Exchange Commission, including its Quarterly Report
on Form 10-Q for the fiscal quarter ended September 30, 2018, and
any other SEC filings that Achillion makes from time to time.
In addition, any forward-looking statement in
this press release represents Achillion's views only as of the date
of this press release and should not be relied upon as representing
its views as of any subsequent date. Achillion disclaims any duty
to update any forward-looking statement, except as required by
applicable law.
Source: Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Sep 2023 to Sep 2024